Novelix Pharma.

Market Cap: Micro Cap
Industry: Retailing
ISIN: INE314I01036
NSEID:
BSEID: 536565
View on BSE

INR

53.60

-0.7 (-1.29%)

BSENSE

Jan 19

BSE+NSE Vol: 7.09 k

{
  "main_header": {
    "sid": 200695,
    "name": "Novelix Pharma.",
    "stock_name": "Novelix Pharma.",
    "full_name": "Novelix Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/novelix-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "53.60",
    "chg": -0.7,
    "chgp": "-1.29%",
    "dir": -1,
    "prev_price": "54.30",
    "mcapval": "92.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 536565,
    "symbol": "",
    "ind_name": "Retailing",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE314I01036",
    "curr_date": "Jan 19",
    "curr_time": "",
    "bse_nse_vol": "7.09 k",
    "exc_status": "Active",
    "traded_date": "Jan 19, 2026",
    "traded_date_str": "2026 01 19",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/novelix-pharma-200695-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Novelix Pharmaceuticals Downgraded to Sell Amid Mixed Technicals and Valuation Concerns",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/novelix-pharmaceuticals-downgraded-to-sell-amid-mixed-technicals-and-valuation-concerns-3782562",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/NovelixPharmace_mojoScore_3782562.png",
        "date": "2026-01-06 08:20:00",
        "description": "Novelix Pharmaceuticals Ltd has seen its investment rating downgraded from Hold to Sell as of 5 January 2026, reflecting a combination of deteriorating technical indicators, expensive valuation metrics, and weak long-term fundamentals despite recent positive quarterly financial results."
      },
      {
        "title": "Novelix Pharmaceuticals Ltd is Rated Hold",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/novelix-pharmaceuticals-ltd-is-rated-hold-3769566",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/NovelixPharmace_mojoScore_3769566.png",
        "date": "2025-12-25 15:13:16",
        "description": "Novelix Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 08 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 December 2025, providing investors with the latest insights into its performance and outlook."
      },
      {
        "title": "Novelix Pharmaceuticals Faces Intense Selling Pressure Amid Consecutive Losses",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/novelix-pharmaceuticals-faces-severe-selling-pressure-hits-lower-circuit-amid-market-turmoil-3748017",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/NovelixPharmace_only_sellers_3748017.png",
        "date": "2025-12-05 09:30:20",
        "description": "Novelix Pharmaceuticals has encountered significant selling pressure, with the stock registering a sharp decline of 4.99% today and exhibiting a distinct absence of buyers. This marks the third consecutive day of losses, reflecting a sustained period of distress selling that has weighed heavily on investor sentiment."
      },
      {
        "title": "Novelix Pharmaceuticals: Analytical Review Highlights Key Shifts in Market Assessment",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/novelix-pharmaceuticals-downgraded-to-sell-amid-mixed-technicals-and-valuation-concerns-3747716",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/NovelixPharmace_mojoScore_3747716.png",
        "date": "2025-12-05 08:06:04",
        "description": "Novelix Pharmaceuticals has undergone a notable revision in its market evaluation, reflecting shifts across multiple analytical parameters including quality, valuation, financial trends, and technical indicators. This article examines the underlying factors influencing these changes and their implications for investors within the retailing sector."
      },
      {
        "title": "How has been the historical performance of Novelix Pharma.?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-novelix-pharma-3747097",
        "imagepath": "",
        "date": "2025-12-04 22:46:23",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Revenue and Operating Performance Trends</strong></p>\n<p>Net sales for Novelix Pharma. peaked around the fiscal year ending March 2018 at approximately ₹10.50 crores but have since shown a gradual decline, falling to ₹8.61 crores by March 2022. The total operating income mirrored this trend, with a notable drop from ₹10.50 crores in 2018 to ₹8.61 crores in 2022. The company’s cost structure reveals a significant reliance on the purchase of finished goods, which constituted the largest share of expenditure, increasing from ₹4.12 crores in 2016 to ₹8.26 crores in 2022. Raw material costs remained relatively low but fluctuated, while employee costs showed a modest increase over the years.</p>\n<p>Operating profit margins have deteriorated sharply, with the company reporting negative margins cons..."
      },
      {
        "title": "Novelix Pharmaceuticals Faces Intense Selling Pressure Amid Consecutive Losses",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/novelix-pharmaceuticals-faces-severe-selling-pressure-hits-lower-circuit-amid-market-turmoil-3745843",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/NovelixPharmace_only_sellers_3745843.png",
        "date": "2025-12-04 09:35:28",
        "description": "Novelix Pharmaceuticals Ltd experienced a sharp decline today, marked by exclusive selling activity and a lower circuit lock at Rs 59.75. The stock’s performance contrasts starkly with the broader market, signalling distress selling and heightened investor caution."
      },
      {
        "title": "Novelix Pharmaceuticals Faces Intense Selling Pressure Amid Lower Circuit Lockdown",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/novelix-pharmaceuticals-faces-severe-selling-pressure-amid-lower-circuit-lockdown-3743312",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/NovelixPharmace_only_sellers_3743312.png",
        "date": "2025-12-03 09:40:26",
        "description": "Novelix Pharmaceuticals Ltd experienced a severe downturn on 3 Dec 2025, marked by an exclusive presence of sell orders and a lower circuit lock that halted any buying activity. The stock’s performance sharply contrasted with broader market trends, signalling distress selling and heightened investor caution within the retailing sector."
      },
      {
        "title": "Novelix Pharmaceuticals Surges with Unprecedented Buying Interest and Upper Circuit Lock",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/novelix-pharmaceuticals-hits-upper-circuit-amid-unprecedented-buying-frenzy-3740947",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/NovelixPharmace_only_buyers_3740947.png",
        "date": "2025-12-02 09:35:23",
        "description": "Novelix Pharmaceuticals has witnessed extraordinary buying momentum, locking in an upper circuit with exclusively buy orders in the queue. This remarkable demand, coupled with a string of consecutive gains, signals a potential multi-day circuit scenario for the retailing sector stock."
      },
      {
        "title": "Novelix Pharmaceuticals Surges with Unprecedented Buying Interest and Upper Circuit Momentum",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/novelix-pharmaceuticals-hits-upper-circuit-amid-unprecedented-buying-interest-3737831",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/NovelixPharmace_only_buyers_3737831.png",
        "date": "2025-12-01 09:55:14",
        "description": "Novelix Pharmaceuticals has captured market attention with extraordinary buying interest, registering an upper circuit scenario marked by a complete absence of sellers. This rare market phenomenon signals robust demand and the potential for sustained gains over multiple trading sessions."
      }
    ],
    "total": 98,
    "sid": "200695",
    "stock_news_url": "https://www.marketsmojo.com/news/novelix-pharmaceuticals-200695"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Change in Directorate",
      "datetime": "11-Jan-2026",
      "details": "Submission of Intimation of Confirmation of director appointment in EGM.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Change in Directorate",
      "datetime": "10-Jan-2026",
      "details": "Submission of Confirmation of Appointment as Director.",
      "source": "BSE"
    },
    {
      "caption": "Shareholder Meeting / Postal Ballot-Scrutinizers Report",
      "datetime": "10-Jan-2026",
      "details": "Submission of Voting Results along with Scrutinizers report.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Novelix Pharmaceuticals Ltd has declared <strong>3%</strong> dividend, ex-date: 16 Aug 12",
          "dt": "2012-08-16",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Novelix Pharmaceuticals Ltd has announced <strong>10:1</strong> stock split, ex-date: 04 Oct 10",
          "dt": "2010-10-04",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Novelix Pharmaceuticals Downgraded to Sell Amid Mixed Technicals and Valuation Concerns

2026-01-06 08:20:00

Novelix Pharmaceuticals Ltd has seen its investment rating downgraded from Hold to Sell as of 5 January 2026, reflecting a combination of deteriorating technical indicators, expensive valuation metrics, and weak long-term fundamentals despite recent positive quarterly financial results.

Read full news article

Novelix Pharmaceuticals Ltd is Rated Hold

2025-12-25 15:13:16

Novelix Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 08 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 December 2025, providing investors with the latest insights into its performance and outlook.

Read full news article

Novelix Pharmaceuticals Faces Intense Selling Pressure Amid Consecutive Losses

2025-12-05 09:30:20

Novelix Pharmaceuticals has encountered significant selling pressure, with the stock registering a sharp decline of 4.99% today and exhibiting a distinct absence of buyers. This marks the third consecutive day of losses, reflecting a sustained period of distress selling that has weighed heavily on investor sentiment.

Read full news article

Novelix Pharmaceuticals: Analytical Review Highlights Key Shifts in Market Assessment

2025-12-05 08:06:04

Novelix Pharmaceuticals has undergone a notable revision in its market evaluation, reflecting shifts across multiple analytical parameters including quality, valuation, financial trends, and technical indicators. This article examines the underlying factors influencing these changes and their implications for investors within the retailing sector.

Read full news article

How has been the historical performance of Novelix Pharma.?

2025-12-04 22:46:23

Revenue and Operating Performance Trends

Net sales for Novelix Pharma. peaked around the fiscal year ending March 2018 at approximately ₹10.50 crores but have since shown a gradual decline, falling to ₹8.61 crores by March 2022. The total operating income mirrored this trend, with a notable drop from ₹10.50 crores in 2018 to ₹8.61 crores in 2022. The company’s cost structure reveals a significant reliance on the purchase of finished goods, which constituted the largest share of expenditure, increasing from ₹4.12 crores in 2016 to ₹8.26 crores in 2022. Raw material costs remained relatively low but fluctuated, while employee costs showed a modest increase over the years.

Operating profit margins have deteriorated sharply, with the company reporting negative margins cons...

Read full news article

Novelix Pharmaceuticals Faces Intense Selling Pressure Amid Consecutive Losses

2025-12-04 09:35:28

Novelix Pharmaceuticals Ltd experienced a sharp decline today, marked by exclusive selling activity and a lower circuit lock at Rs 59.75. The stock’s performance contrasts starkly with the broader market, signalling distress selling and heightened investor caution.

Read full news article

Novelix Pharmaceuticals Faces Intense Selling Pressure Amid Lower Circuit Lockdown

2025-12-03 09:40:26

Novelix Pharmaceuticals Ltd experienced a severe downturn on 3 Dec 2025, marked by an exclusive presence of sell orders and a lower circuit lock that halted any buying activity. The stock’s performance sharply contrasted with broader market trends, signalling distress selling and heightened investor caution within the retailing sector.

Read full news article

Novelix Pharmaceuticals Surges with Unprecedented Buying Interest and Upper Circuit Lock

2025-12-02 09:35:23

Novelix Pharmaceuticals has witnessed extraordinary buying momentum, locking in an upper circuit with exclusively buy orders in the queue. This remarkable demand, coupled with a string of consecutive gains, signals a potential multi-day circuit scenario for the retailing sector stock.

Read full news article

Novelix Pharmaceuticals Surges with Unprecedented Buying Interest and Upper Circuit Momentum

2025-12-01 09:55:14

Novelix Pharmaceuticals has captured market attention with extraordinary buying interest, registering an upper circuit scenario marked by a complete absence of sellers. This rare market phenomenon signals robust demand and the potential for sustained gains over multiple trading sessions.